Poietis
A French biotech company developing and producing human tissues using laser-assisted 4D bioprinting for pharmaceutical, cosmetic, and regenerative medicine applications.
- CEO / Founder
- Fabien Guillemot (Founder & CSO)
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $9M
- Latest Round
- Series A
- Key Investors
- Nouvelle-Aquitaine Co-investissement, WiSEED, Bpifrance, Aquiti Gestion
Technology & Products
Key Products
NGB-R platform, NGB-C platform, NGB bioprinting systems, bioprinted human tissues for pharmaceutical, cosmetic, and regenerative medicine applications.
Technological Advantage
The ability to create complex, multi-layered functional tissues provides a significant advantage over traditional 2D cell cultures and extrusion-based 3D models. This leads to more predictive data for drug and cosmetic testing, reducing reliance on animal testing and accelerating product development pipelines.
Differentiation
Value Proposition
To provide more predictive and reliable in-vitro human tissue models for research and testing, while also developing bioprinted tissues for future therapeutic use in regenerative medicine.
How They Differentiate
Poietis differentiates through its high-precision laser-assisted bioprinting technology, which offers superior resolution and cell viability compared to the more common extrusion-based methods used by many competitors. Their focus on 4D bioprinting and developing complex, functional tissues for both in-vitro testing and future therapeutic applications sets them apart.
Market & Competition
Target Customers
Pharmaceutical and cosmetic companies, academic researchers, and clinical partners in regenerative medicine.
Industry Verticals
["Pharmaceuticals","Cosmetics","Biotechnology","Regenerative Medicine"]
Competitors
CELLINK, Organovo, EnvisionTEC
Growth & Milestones
Major Milestones
["2014: Company founded.","2017: Commercial launch of the Poieskin® tissue model.","2018: Raised €5M in a Series A funding round.","2018: Established key partnerships with major pharmaceutical (Servier) and chemical (BASF) companies.","2022: Installed the NGB-C bioprinter in a GMP-compliant facility at the University of Barcelona to advance towards clinical applications."]
Notable Customers
Servier, AP-HM (Assistance Publique – Hôpitaux de Marseille)